Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351043 | 0.88 | ALDH1A1 (0.39) | CPN1CPB2GRB2FADS1F10 | |
| SCHEMBL2352833 | 0.88 | PLAU (0.38) | CPN1CPB2GRB2FADS1ITGB3 | |
| SCHEMBL2355830 | 0.86 | NPSR1 (0.38) | ITGB3ITGA2BMEN1KMT2APLAU | |
| SCHEMBL2353245 | 0.84 | CYP2D6 (0.41) | F10ITGB3ITGA2B | |
| SCHEMBL2356284 | 0.84 | GRB2 (0.37) | CPN1CPB2GRB2FADS1F10 | |
| SCHEMBL2348810 | 0.83 | KDM4E (0.41) | GRB2ALDH1A1 | |
| SCHEMBL2349923 | 0.83 | CPN1 (0.58) | CPN1CPB2FADS1F10ITGB3 | |
| SCHEMBL23752186 | 0.82 | LMNA (0.44) | F10ITGB3ITGA2BMEN1KMT2A | |
| SCHEMBL2355128 | 0.82 | LMNA (0.44) | F10ITGB3ITGA2BMEN1KMT2A | |
| SCHEMBL2353764 | 0.82 | MMP3 (0.37) | GRB2FADS1F10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | claimed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | claimed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | claimed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | claimed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | claimed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | claimed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | claimed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | claimed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | claimed |
| CN-1656107-A | Plasma carboxypeptidase B inhibitors | SCHERING AG (DE) | 2005-08-17 | — | — | CN | claimed |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
| CN-1656107-A | Plasma carboxypeptidase B inhibitors | SCHERING AG (DE) | 2005-08-17 | — | — | CN | disclosed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SERPINB1, TFPI, TFPI2 | CPN1 508/4885CPB2 73/4885GRB2 3529/4885 |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | CPN1 10/4885CPB2 2/4885GRB2 3581/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | CPN1 10/4885CPB2 2/4885GRB2 3581/4885 |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | TFPI, TFPI2, TNNI3 | CPN1 1279/4885CPB2 78/4885GRB2 3437/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | CPN1 10/4885CPB2 2/4885GRB2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.